Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -109.52% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | -109.52% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about future developments. They acknowledged the challenges faced but remained focused on their strategic goals.
Management highlighted ongoing progress in their pipeline despite the EPS miss.
They emphasized their commitment to advancing their drug development programs.
Ionis Pharmaceuticals reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock reacted positively, gaining 1.3%, likely due to management's optimistic tone about their ongoing projects. The lack of revenue data and guidance leaves some uncertainty about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Leidos Holdings, Inc.